Identifying people with multiple sclerosis in the Canadian Primary Care Sentinel Surveillance Network [0.03%]
在加拿大初级保健哨点监测网络中识别多发性硬化患者
Ruth Ann Marrie,Leanne Kosowan,Carole Taylor et al.
Ruth Ann Marrie et al.
Background: We validated a case definition for multiple sclerosis using a clinical cohort linked with the Manitoba Primary Care Research Network of the Canadian Primary Care Sentinel Surveillance Network, and applied this...
Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero [0.03%]
多发性硬化症患者的意外怀孕及胎儿药物暴露风险
Andrew L Smith,Jeffrey A Cohen,Daniel Ontaneda et al.
Andrew L Smith et al.
Background: Multiple sclerosis is a central nervous system demyelinating disease that affects women of reproductive potential. It is important to identify the frequency and risk factors of unplanned or disease-modifying t...
Is multiple sclerosis progression associated with the HLA-DR15 haplotype? [0.03%]
HLA-DR15等位基因与多发性硬化症进展的关系研究
Klarissa Hanja Stürner,Inessa Siembab,Gerhard Schön et al.
Klarissa Hanja Stürner et al.
Background: The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. ...
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme [0.03%]
醋酸格拉替雷作为反复发作性多发性硬化症临床和成本效益治疗长达十年：英国风险共享计划最终结果
G Giovannoni,P A Brex,D Dhiraj et al.
G Giovannoni et al.
Background: The UK Risk Sharing Scheme (RSS) provided information on the effect of first-line multiple sclerosis (MS) disease-modifying treatments on long-term disability. ...
High serum concentration of vitamin D may protect against multiple sclerosis [0.03%]
高维生素D血清浓度可能有助预防多发性硬化症
Martin Biström,Lucia Alonso-Magdalena,Oluf Andersen et al.
Martin Biström et al.
Background: High 25-hydroxyvitamin D concentrations have been associated with a reduced risk of multiple sclerosis, with indications of a stronger effect among young individuals. ...
Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC [0.03%]
延释富马酸二甲酯对复发缓解型多发性硬化症患者报告结果和临床指标有效性的研究：PROTEC研究
T Berger,B Brochet,L Brambilla et al.
T Berger et al.
Background: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease. Object...
Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms [0.03%]
神经病质量生命量表（Neuro-QoL™）短期疗效判定在多发性硬化症中患者报告结果的验证
Luis D Medina,Stephanie Torres,Enrique Alvarez et al.
Luis D Medina et al.
Background: Patient-reported outcome (PRO) measures have been shown to be effective for tracking treatment outcomes in multiple sclerosis (MS). However, collecting PROs as part of the clinical standard of care can be time...
Validation of a consumer-grade activity monitor for continuous daily activity monitoring in individuals with multiple sclerosis [0.03%]
validation of a consumer-grade activity monitor for the continuous daily activity monitoring in multiple sclerosis patients
Valerie J Block,Chao Zhao,Jill A Hollenbach et al.
Valerie J Block et al.
Background: Technological advancements of remote-monitoring used in clinical-care and research require validation of model updates. Objectives: ...
ABO blood group distributions in multiple sclerosis patients from Basque Country; O- as a protective factor [0.03%]
巴斯克地区多发性硬化症患者的ABO血型分布；O型具有保护作用
Itziar Lopetegi,Amaia Muñoz-Lopetegi,Maialen Arruti et al.
Itziar Lopetegi et al.
Background: The relation between ABO/Rh groups and multiple sclerosis (MS) has been proposed in several studies, however there is a controversy about the role of these groups in the disease. Although it has been reported ...
Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial [0.03%]
多发性硬化症延迟释放富马酸二甲酯干预期间的肠道微生物组组成-一项试点试验
C Storm-Larsen,K-M Myhr,E Farbu et al.
C Storm-Larsen et al.
Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing-remitting multiple sclerosis, which has been associ...